Valuation: Moderna, Inc.

Market Cap 79.4B 69.82B 66.04B 59.91B 113B 7,620B 113B 789B 305B 3,889B 298B 292B 12,496B P/E 2026 *
-23.7x
P/E 2027 * -41.5x
Enterprise Value 75.75B 66.61B 63B 57.15B 107B 7,270B 108B 753B 291B 3,710B 284B 278B 11,921B EV / Sales 2026 *
36.1x
EV / Sales 2027 * 31.7x
Free-Float
92.68%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2011
Director of Finance/CFO 49 06/09/2022
President 50 01/11/2024
Director TitleAgeSince
Chairman 63 01/02/2012
Director/Board Member 54 01/03/2011
Director/Board Member 69 11/12/2019
Change 5-day change 1-year change 3-year change Capi.($)
+1.01%-39.82% - - 79.4B
-0.80%+28.07%+705.55%+98.39% 79.4B
-4.54%-4.15%+33.40%-9.65% 78.69B
+2.80%+3.60%-6.34%-27.82% 59.52B
-0.89%+2.11%+7.92%+170.43% 46.58B
+2.49%+0.14%-8.95%+33.71% 46.53B
+0.48%+6.12%+66.48%-11.20% 33.63B
+0.75%-0.39%+50.93%+111.17% 25.11B
-3.56%-0.47%+3.11%+135.37% 22.13B
+0.73%-1.70%+61.19%+100.64% 15.31B
Average -0.06%+4.30%+101.48%+66.78% 45.21B
Weighted average by Cap. -0.12%+6.71%+154.20%+53.71%

Financials

2026 *2027 *
Net sales 2.1B 1.85B 1.75B 1.58B 2.98B 202B 2.99B 20.87B 8.06B 103B 7.89B 7.72B 331B 2.44B 2.14B 2.03B 1.84B 3.46B 234B 3.47B 24.23B 9.36B 119B 9.15B 8.95B 384B
Net income -3.31B -2.91B -2.76B -2.5B -4.7B -318B -4.72B -32.92B -12.72B -162B -12.44B -12.17B -521B -1.94B -1.71B -1.62B -1.47B -2.76B -187B -2.77B -19.32B -7.46B -95.25B -7.3B -7.14B -306B
Net Debt -3.65B -3.21B -3.04B -2.76B -5.18B -351B -5.21B -36.3B -14.02B -179B -13.71B -13.42B -575B -2.17B -1.91B -1.8B -1.64B -3.08B -208B -3.09B -21.56B -8.33B -106B -8.15B -7.97B -342B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB